JPRN-UMIN000035248招募中未知
Safety and efficacy of pemafibrate (Parmodia) for patients having dyslipidemia and non-alcoholic fatty liver disease (NAFLD) - Safety and efficacy of pemafibrate (Parmodia) for patients having dyslipidemia and non-alcoholic fatty liver disease (NAFLD)
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 90years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Creatinine > 1.5 mg/dL 2. Past history of myopathy and renal dysfunction by fibrate drugs 3. During Pregnancy and breast-feeding 4. Humans who were judged as not-suitable for this trial
研究者
相似试验
招募中
Unknown
The efficacy and safety of the pemafibrate in subjects with dyslipidemia and severely decreased renal function; a prospective observational studyDyslipidemia, chronic kidney diseaseJPRN-UMIN000053168Kushiro Red Cross Hospital60
尚未招募
不适用
Clinical benefit of pemafibrate in patients with primary biliary cholangitis (PBC) with dyslipidemiaprimary biliary cholangitisJPRN-UMIN000039350Shinshu University Faculty of Medicine, Department of Gastroenterology60
招募中
2 期
Randomized controlled trial of pemafibrate and fenofibrate for NAFLD with hypertriglyceridemiaJPRN-jRCTs031200280Iwaki Michihiro360
已完成
不适用
Investigating the efficacy and safety of Plasmapheresis in patients with Moderate to severe COVID-19IRCT20080901001165N58Bagheiat-allah University of Medical Sciences100
已完成
2 期
Efficacy and safety study of defibrotide (DF) for the treatment of venoocclusive disease (VOD).Veno Occlusive DiseaseJPRN-UMIN000013454Fukushima Medical University Hospital Atsushi Kikuta20